Imunon (IMNN) risk factors, FY2024 10-K

RISKS RELATED TO OUR BUSINESS AND OPERATIONS

1. 01We have a history of significant losses from operations and expect to continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability
2. 02We might not be able to continue as a going concern, which could cause our stockholders to lose most or all of their investment
3. 03Drug development is an inherently uncertain process with a high risk of failure at every stage of development
4. 04New gene-based products for therapeutic applications are subject to extensive regulation by the FDA and comparable agencies in other countries. The precise regulatory requirements with which we will have to comply, now and in the future, are uncertain due to the novelty of the gene-based products we are developing
5. 05If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
6. 06We do not independently conduct clinical trials for our drug candidates. We rely, and expect to continue to rely, on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor our clinical trials
7. 07Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality
8. 08An important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into strategic alliances with pharmaceutical companies, research institutions or other industry participants to advance our programs and enable us to maintain our financial and operational capacity
9. 09We may not successfully engage in future strategic transactions, which could adversely affect our ability to develop and commercialize drug candidates, impact our cash position, increase our expenses and present significant distractions to our management
10. 10We have obtained Orphan Drug Designation for IMNN-001 and may seek Orphan Drug Designation for other drug candidates, but we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity
11. 11Fast Track designation may not actually lead to a faster development or regulatory review or approval process
12. 12The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of biopharmaceutical products
13. 13Ongoing legislative and regulatory changes affecting the healthcare industry could have a material adverse effect on our business
14. 14We may fail to comply with evolving European and other privacy laws
15. 15The success of our products, if approved, may be harmed if the government, private health insurers and other third-party payers do not provide sufficient coverage or reimbursement
16. 16Our products, if approved, may not achieve sufficient acceptance by the medical community to sustain our business
17. 17We have no internal sales or marketing capability. If we are unable to create sales, marketing and distribution capabilities or enter into alliances with others possessing such capabilities to perform these functions, we will not be able to commercialize our products, if approved, successfully
18. 18Our success will depend in part on our ability to grow and diversify, which in turn will require that we manage and control our growth effectively
19. 19We face intense competition and the failure to compete effectively could adversely affect our ability to develop and market our products, if approved
20. 20We may be subject to significant product liability claims and litigation
21. 21Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs
22. 22Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation
23. 23Litigation and other legal proceedings against the Company, which may arise in the ordinary course of Company’s business, could be costly and time consuming to defend

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

1. 24Our business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights under these agreements could impair our ability to develop and market our products, if approved
2. 25If any of our pending patent applications are not issued, or are deemed invalid following issuance, we may lose valuable intellectual property protection
3. 26We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition
4. 27We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights

RISKS RELATED TO OUR SECURITIES

1. 28The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation
2. 29Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards
3. 30Future sales of our common stock in the public market could cause our stock price to fall
4. 31Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants
5. 32Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and share price
6. 33Our ability to use net operating losses to offset future taxable income is subject to certain limitations
7. 34We have never paid cash dividends on our common stock in the past and do not anticipate paying cash dividends on our common stock in the foreseeable future
8. 35Anti-takeover provisions in our charter documents and Delaware law could prevent or delay a change in control